WO1999022722A3 - Use of macrolides for the treatment of cancer and macular degeneration - Google Patents

Use of macrolides for the treatment of cancer and macular degeneration Download PDF

Info

Publication number
WO1999022722A3
WO1999022722A3 PCT/US1998/023043 US9823043W WO9922722A3 WO 1999022722 A3 WO1999022722 A3 WO 1999022722A3 US 9823043 W US9823043 W US 9823043W WO 9922722 A3 WO9922722 A3 WO 9922722A3
Authority
WO
WIPO (PCT)
Prior art keywords
macular degeneration
macrolides
cancer
treatment
compound
Prior art date
Application number
PCT/US1998/023043
Other languages
French (fr)
Other versions
WO1999022722A2 (en
Inventor
Yat Sun Or
Jacob J Plattner
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002307850A priority Critical patent/CA2307850A1/en
Priority to HU0100012A priority patent/HUP0100012A3/en
Priority to BR9813318-7A priority patent/BR9813318A/en
Priority to PL98340604A priority patent/PL340604A1/en
Priority to KR1020007004625A priority patent/KR20010031577A/en
Priority to AU12067/99A priority patent/AU1206799A/en
Priority to JP2000518656A priority patent/JP2001521891A/en
Priority to SK617-2000A priority patent/SK6172000A3/en
Application filed by Abbott Lab filed Critical Abbott Lab
Priority to IL13551898A priority patent/IL135518A0/en
Priority to EP98955206A priority patent/EP1027060A2/en
Publication of WO1999022722A2 publication Critical patent/WO1999022722A2/en
Publication of WO1999022722A3 publication Critical patent/WO1999022722A3/en
Priority to NO20002189A priority patent/NO20002189L/en
Priority to BG104436A priority patent/BG104436A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A method for treating tumors and macular degeneration in a human or veterinary patient comprising administering a compound selected from the group consisting of (I), (II), (III), (IV), (V), (VI), (VII), and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound thereof.
PCT/US1998/023043 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration WO1999022722A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2000518656A JP2001521891A (en) 1997-10-31 1998-10-30 Use of macrolides for treating tumors and macular degeneration
BR9813318-7A BR9813318A (en) 1997-10-31 1998-10-30 Process of treating tumors and macular degeneration in a human or veterinary patient, pharmaceutical composition for treating tumors and macular degeneration in a human or veterinary patient
PL98340604A PL340604A1 (en) 1997-10-31 1998-10-30 Application of macrolydes in treating tumours and maculopathy
KR1020007004625A KR20010031577A (en) 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration
AU12067/99A AU1206799A (en) 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration
CA002307850A CA2307850A1 (en) 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration
SK617-2000A SK6172000A3 (en) 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration
HU0100012A HUP0100012A3 (en) 1997-10-31 1998-10-30 Use for macrolides for the treatment of cancer and macular degeneration
IL13551898A IL135518A0 (en) 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration
EP98955206A EP1027060A2 (en) 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration
NO20002189A NO20002189L (en) 1997-10-31 2000-04-27 Use of macrolides for the treatment of cancer and mucous degeneration
BG104436A BG104436A (en) 1997-10-31 2000-05-15 The administration of macrolides for the treatment of cancer and macular degeneration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96147397A 1997-10-31 1997-10-31
US08/961,473 1997-10-31

Publications (2)

Publication Number Publication Date
WO1999022722A2 WO1999022722A2 (en) 1999-05-14
WO1999022722A3 true WO1999022722A3 (en) 1999-08-05

Family

ID=25504514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/023043 WO1999022722A2 (en) 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration

Country Status (17)

Country Link
EP (1) EP1027060A2 (en)
JP (1) JP2001521891A (en)
KR (1) KR20010031577A (en)
CN (1) CN1278178A (en)
AR (1) AR043071A1 (en)
AU (1) AU1206799A (en)
BG (1) BG104436A (en)
BR (1) BR9813318A (en)
CA (1) CA2307850A1 (en)
HU (1) HUP0100012A3 (en)
IL (1) IL135518A0 (en)
NO (1) NO20002189L (en)
PL (1) PL340604A1 (en)
SK (1) SK6172000A3 (en)
TR (1) TR200001147T2 (en)
WO (1) WO1999022722A2 (en)
ZA (1) ZA989885B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486960B2 (en) 2006-03-23 2013-07-16 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US9381153B2 (en) 2005-02-09 2016-07-05 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60140936D1 (en) 2000-04-13 2010-02-11 Biotica Tech Ltd GLYCOSYLATED HYBRID COMPOUNDS, THEIR PREPARATION AND USE
JP2006511475A (en) 2002-09-18 2006-04-06 トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア Method for suppressing choroidal neovascular disease
TW200420573A (en) 2002-09-26 2004-10-16 Rib X Pharmaceuticals Inc Bifunctional heterocyclic compounds and methods of making and using same
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
CA2520732C (en) 2003-03-28 2012-12-04 Sloan-Kettering Institute For Cancer Research Migrastatin analogs and uses thereof
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
EP1723159B1 (en) * 2004-02-27 2019-06-12 Melinta Therapeutics, Inc. Macrocyclic compounds and methods of making and using the same
CN108101948A (en) * 2004-02-27 2018-06-01 瑞伯-X医药品有限公司 Macrocyclic compound and its making and use method
JP5149001B2 (en) 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Migrastatin analogues in the treatment of cancer
EP1805161B1 (en) 2004-09-23 2014-05-07 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
WO2007011880A2 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
EP1934237A2 (en) 2005-08-24 2008-06-25 Rib-X Pharmaceuticals, Inc. Triazole compounds and methods of making and using the same
JP5395432B2 (en) 2005-08-24 2014-01-22 リブ−エックス ファーマシューティカルズ，インコーポレイテッド Triazole compounds and methods for making and using the same
JP5528708B2 (en) 2006-02-09 2014-06-25 参天製薬株式会社 Stable formulations and methods for preparing and using them
CN106317146B (en) * 2015-06-18 2019-06-21 沈阳药科大学 Bicyclic clarithomycin derivative and its as tumour cell increment inhibitor purposes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0426029A1 (en) * 1989-10-30 1991-05-08 Abbott Laboratories Injectable formulation for lipophilic drugs
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0426029A1 (en) * 1989-10-30 1991-05-08 Abbott Laboratories Injectable formulation for lipophilic drugs
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. YATSUNAMI ET AL.: "Clarithromycin is a potent inhibitor of tumor-induced angiogenesis.", RES. EXP. MED, vol. 197, no. 4, 1997, pages 189 - 197, XP002101275 *
T. ISHII ET AL.: "TAN-1323 C and D, new concanamycin-group antibiotics: detection of the angiostatic activity with a wide range of macrolide antibiotics.", J. ANTIBIOT., vol. 48, no. 1, 1995, pages 12 - 20, XP002101276 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9381153B2 (en) 2005-02-09 2016-07-05 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions
US8486960B2 (en) 2006-03-23 2013-07-16 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US9452156B2 (en) 2006-03-23 2016-09-27 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions

Also Published As

Publication number Publication date
NO20002189L (en) 2000-06-28
PL340604A1 (en) 2001-02-12
CA2307850A1 (en) 1999-05-14
JP2001521891A (en) 2001-11-13
AU1206799A (en) 1999-05-24
HUP0100012A2 (en) 2001-05-28
TR200001147T2 (en) 2000-08-21
BG104436A (en) 2000-12-29
SK6172000A3 (en) 2001-03-12
EP1027060A2 (en) 2000-08-16
WO1999022722A2 (en) 1999-05-14
CN1278178A (en) 2000-12-27
IL135518A0 (en) 2001-05-20
HUP0100012A3 (en) 2003-07-28
ZA989885B (en) 1999-05-05
AR043071A1 (en) 2005-07-20
NO20002189D0 (en) 2000-04-27
KR20010031577A (en) 2001-04-16
BR9813318A (en) 2000-08-22

Similar Documents

Publication Publication Date Title
WO1999022722A3 (en) Use of macrolides for the treatment of cancer and macular degeneration
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
WO1998029110A3 (en) Formulation and method for treating neoplasms by inhalation
AU3581697A (en) Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin
HUT76258A (en) Compositions comprising dna damaging agents and p53, and methods for uses thereof
AU4564200A (en) Method for treating cancer using camptothecin derivatives and 5-fluorouracil
HUP0301046A3 (en) Quinazoline derivatives for the treatment of tumours, process for their preparation and pharmaceutical compositions containing them
EP1466606A3 (en) Use of inosine for the manufacture of a medicament for stimulating axonal outgrowth of central nervous system neurons
HUP0203238A3 (en) Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them
AU3206299A (en) Method and apparatus for combining injury-mediated therapy and drug delivery
IL133784A (en) Dolastatin 15 derivatives, pharmaceutical compositions comprising them and their use in medicaments for treating cancer
HK1048986B (en) 2'-substituted 1, 1'-iphenyl-2-carbonamides, method for the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds
BG103647A (en) Cisplatina containing microgranules
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
HK1047707A1 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
EP0391644A3 (en) Aryl-substituted rhodanine derivatives
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
AU1277792A (en) Compositions for topical administration containing fluticasone propionate and oxiconazole or its salts
WO2000008007A3 (en) Cyclopentabenzofuran derivatives and their use
EP0281070A3 (en) Pharmaceutical composition for the treatment of cancer
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
EP0744176A3 (en) Methods for inhibiting bone loss
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
MXPA02005045A (en) Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating cancer.
EP0821969A3 (en) Medicinal Composition comprising TCF-II

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 135518

Country of ref document: IL

Ref document number: 98810825.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 503824

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12067/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2000-1524

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2307850

Country of ref document: CA

Ref document number: 2307850

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2000 518656

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 6172000

Country of ref document: SK

Ref document number: 2000/01147

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1020007004625

Country of ref document: KR

Ref document number: 1998955206

Country of ref document: EP

Ref document number: PA/A/2000/004225

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1998955206

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-1524

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007004625

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998955206

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020007004625

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2000-1524

Country of ref document: CZ